ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Chitosan and L-histidine coated biofunctional TiO₂ composite with enhanced ROS-mediated antimicrobial and anticancer efficacy for biomedical applications.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Societies continue to face the urgent challenge of developing effective, safe, and stable nanoparticles with promising biomedical applications. Herein, the present study synthesis chitosan and L-Histidine dually coated titanium dioxide (TiCSLH) nanocomposite (NC) by chemical co-precipitation method. The antimicrobial performance of TiO₂ nanoparticles is closely linked to their physicochemical properties, such as reduced particle size, increased bandgap, and the presence of oxygen vacancies, all of which collectively enhance reactive oxygen species (ROS) generation and inhibit microbial growth. Structural analyses using XRD and TEM confirmed that TiCSLH nanoparticles possess an anatase phase and a spherical morphology. Compared to TiO₂, TiCSLH nanoparticles demonstrated significantly enhanced antimicrobial activity against MRSA, E. coli, K. pneumoniae, P. aeruginosa and C. albicans strains, as evidenced by larger zones of inhibition from 23-24 mm. This enhanced efficacy is attributed to their smaller particle size (~ 26 ± 3 nm), wider bandgap (3.34 eV), and prominent oxygen vacancy-related emissions at 518 and 531 nm, which facilitate increased ROS production, resulting in cellular membrane disruption and microbial death. Furthermore, compared to TiO
Indexed as
Identifiers
40569371What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.